Dean Chiang in Forbes: ‘Engineering Medicine’
Fifty years ago, clinical pharmacologist Harry Shirkey noted that children are often “therapeutic orphans” in biomedical research — a trend that continues, with pediatric biomedical advances lagging behind those for adults, and rare pediatric-only conditions, or “orphan diseases,” lacking a market sufficient to drive intervention. Additionally, personalization, miniaturization and automation hold promise for reshaping drug development.
In a recent Forbes article, Mung Chiang, Purdue executive vice president for strategic initiatives and the John A. Edwardson Dean of the College of Engineering, presents engineering-medicine collaboration is a catalyst for progress in both of these areas.
Pointing to the Engineering-Medicine partnership between Purdue University and Indiana University, he writes that “American universities have an opportunity to serve as a development force to conduct research in therapeutics and biomedical technologies for children and adolescents.” In addition, citing the Indiana Life Sciences Manufacturing Summit, Chiang calls on academia, government and industry to build “an innovation ecosystem in engineering medicine” that “will be a critical part of a long-term strategy to enhance US manufacturing sovereignty and competitiveness.”
Read the entire piece here: Engineering Medicine
